In Re MAGNOLIA MEDICAL TECHNOLOGIES, INC.

The United States Court of Appeals for the Federal Circuit, in *Magnolia Medical Technologies, Inc. v. Kurin, Inc.*, affirmed a district court's judgment of non-infringement concerning two patents related to blood sequestration devices. The Federal Circuit upheld the district court's post-jury-verdict clarification of claim terms, ruling that the terms "vent" and "seal" in one patent required separate structures, which the accused product lacked. Furthermore, the court affirmed that the term "diverter" in a second patent was a means-plus-function limitation under 35 U.S.C. § 112(f), thereby restricting its scope to the structures disclosed in the patent specification. This decision underscores critical aspects of patent claim construction, particularly regarding the interpretation of multiple claim limitations and the application of means-plus-function claiming, with significant implications for patent holders and litigators in the medical device industry.

The landscape of patent litigation, particularly in the highly innovative medical device sector, frequently hinges on the precise interpretation of patent claims. A recent precedential decision by the United States Court of Appeals for the Federal Circuit in *Magnolia Medical Technologies, Inc. v. Kurin, Inc.*, Appeal No. 2024-2001 (Fed. Cir. Mar. 6, 2026), offers crucial guidance on claim construction, the application of means-plus-function limitations, and the permissible scope of judicial clarification post-verdict. This case, involving blood sequestration devices designed to improve the accuracy of blood tests, saw Magnolia Medical Technologies, Inc. ("Magnolia") assert infringement of two of its patents against Kurin, Inc. ("Kurin").

The Federal Circuit's affirmation of the district court's judgment of non-infringement provides valuable insights for practitioners navigating the complexities of patent claim interpretation. The court's analysis centered on whether specific claim terms required distinct structural components and whether a particular term invoked means-plus-function treatment, thereby limiting its scope. The outcome reinforces established principles of patent law while also addressing procedural aspects of claim construction, particularly the timing and nature of judicial clarification.

This article delves into the Federal Circuit's reasoning in *Magnolia Medical Technologies*, examining the court's approach to claim construction for both independently recited limitations and means-plus-function terms. It will explore the implications of the court's findings on the requirement for separate structures, the rejection of claim differentiation arguments, and the significance of the decision for patent prosecution and litigation strategies.

The dispute in *Magnolia Medical Technologies, Inc. v. Kurin, Inc.* arose from allegations of patent infringement concerning medical devices designed to reduce contamination in blood cultures. Magnolia Medical Technologies, Inc. held U.S. Patent No. 10,039,483 (the "'483 patent") and U.S. Patent No. 9,855,001 (the "'001 patent"), both directed to improved products for taking blood samples by sequestering the initial, potentially contaminated, portion of the blood draw. Kurin, Inc. manufactured the "Kurin Lock," an accused device that also aims to separate the initial blood draw using a porous plug.

At the district court level, the case involved two primary claim construction issues. For the '001 patent, the central question was whether the term "diverter" should be construed as a means-plus-function limitation under 35 U.S.C. § 112(f). The district court determined it was, leading to a stipulation of non-infringement for that patent. For the '483 patent, the case proceeded to trial, where a jury initially found infringement. However, the district court subsequently granted Kurin's post-trial motion for judgment as a matter of law (JMOL), finding no infringement. This JMOL was based on the court's interpretation that the "vent" and "seal" limitations in the '483 patent required separate structures, a condition not met by Kurin's single porous plug.

The appeal to the Federal Circuit challenged both the district court's construction of "diverter" and its JMOL ruling regarding the "vent" and "seal" limitations. The Federal Circuit's review thus encompassed fundamental principles of patent claim construction, including the interpretation of explicitly recited structural elements and the application of the statutory framework for functional claiming.

The Federal Circuit's decision meticulously addressed two pivotal claim construction issues. First, regarding the '483 patent, Magnolia challenged the district court's grant of JMOL, arguing that the court improperly adopted a late claim construction by requiring separate structures for the "vent" and "seal" limitations. The Federal Circuit disagreed, holding that the district court's decision merely "clarified" the plain and ordinary meaning of the terms, which was permissible in a JMOL setting. Citing *Becton, Dickinson & Co. v. Tyco Healthcare Group, LP*, the court affirmed that such clarification was not an untimely new construction but an elaboration inherent in the plain-language reading.

On the merits of the "vent" and "seal" limitations, the Federal Circuit concluded that the claim language, which recited "a fluid reservoir that had a 'vent' and a 'seal'," inherently required two separate structures. Magnolia's accused product, the Kurin Lock, utilized a single porous plug that functioned first as a vent and then, upon contact with blood, as a seal. The court found that a single structure performing both functions did not satisfy the claim's requirement for distinct "vent" and "seal" components. Magnolia's argument based on claim differentiation, suggesting that dependent claim 6 (which described the seal preventing airflow "through the vent") would be rendered superfluous if separate structures were required, was also rejected. The Federal Circuit clarified that claim differentiation cannot override the clear implication of the claim language, citing *Clearstream Wastewater Systems, Inc. v. Hydro-Action, Inc.*

Second, concerning the '001 patent, the Federal Circuit affirmed the district court's construction of "diverter" as a means-plus-function term under 35 U.S.C. § 112(f). The court noted that while the term "diverter" itself does not use the word "means," it is a functional label that, in context, does not name a particular structure. Consequently, the claim was limited to the corresponding structures disclosed in the patent specification and their equivalents. Since the parties had stipulated that Kurin's device lacked the required structure under this construction, the Federal Circuit affirmed the finding of non-infringement for the '001 patent.

The Federal Circuit's comprehensive analysis in *Magnolia Medical Technologies* reinforces the importance of precise claim drafting and the potential pitfalls of relying on a single structural element to satisfy multiple, independently recited claim limitations. The decision also highlights the enduring relevance of 35 U.S.C. § 112(f) in determining the scope of functionally claimed elements, even when the explicit "means for" language is absent. The court's willingness to affirm a post-verdict clarification of claim terms further underscores the judiciary's role in ensuring accurate claim interpretation throughout the litigation process.

The Federal Circuit's decision in *Magnolia Medical Technologies, Inc. v. Kurin, Inc.* serves as a critical reminder for patent practitioners regarding the meticulous nature of claim construction in patent litigation. For patent drafters, the case emphasizes the need for clarity and specificity, particularly when defining multiple functional or structural elements within a claim. If distinct functions are intended to be performed by separate structures, the claim language should unequivocally reflect this, avoiding ambiguity that could lead to a narrow interpretation or a finding of non-infringement. The rejection of the claim differentiation argument as a means to overcome clear claim language further underscores this point.

For litigators, the ruling highlights the importance of establishing a consistent and well-supported claim construction theory early in the proceedings. The Federal Circuit's affirmation of the district court's post-verdict clarification of claim terms, rather than deeming it an untimely new construction, suggests that courts retain significant latitude to ensure accurate interpretation, even after a jury verdict. Practitioners should be prepared for robust claim construction arguments at all stages of litigation and ensure that their infringement theories align precisely with the construed claims. This case ultimately reinforces that the precise wording of patent claims, and their interpretation in light of the specification, remains paramount in determining the scope of patent protection and the outcome of infringement disputes.